Craif raised $33 million in a Series D financing to accelerate its entry into the U.S., with a near-term plan to generate clinical evidence for a urine-based pancreatic cancer test backed by microRNA analysis and AI. The company’s technology is being positioned as a simple screening approach beginning with pancreatic cancer, followed by additional expansion opportunities. In parallel, Craif said it is scaling its San Diego lab and preparing for a U.S. clinical trial, including pursuing CLIA certification and ramping sequencing capacity. The company is targeting an interim readout within 12 to 18 months, with full study completion expected around 24 to 26 months. If enrollment and reimbursement plans hold, Craif’s trial execution could become a practical reference point for how early screening diagnostics translate from funding and local validation to regulatory-grade clinical utility in the U.S.